HypErthermia as an Additional Treatment for the Biology and Experience of Depression
| Condition | Major Depressive Disorder |
|---|---|
| Phase | N/A |
| Sponsor | University of California, San Francisco |
| Status | Completed |
| Enrollment | 16 participants |
| Interventions | Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH) |
| Start date | Oct 11, 2021 |
| Completion date | Mar 1, 2023 |
| Results posted | Jun 12, 2024 |
Summary
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or older with major depressive disorder (MDD).
Average Number of Planned WBH Sessions Completed
| Cognitive Behavioral Therapy (CBT) and 8 Sessions Whole-Body Hyperthermia (WBH) | 7.83 ± 0.41 Count of WBH Sessions |
|---|---|
| Cognitive Behavioral Therapy (CBT) and 4 Sessions Whole-Body Hyperthermia (WBH) | 3.20 ± 1.40 Count of WBH Sessions |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital